Methylglyoxal metabolism in trypanosomes and leishmania  by Wyllie, Susan & Fairlamb, Alan H.
RM
S
D
a
A
A
K
T
L
M
G
T
D
C
1
p
T
c
n
l
w
N
g
1
dSeminars in Cell & Developmental Biology 22 (2011) 271–277
Contents lists available at ScienceDirect
Seminars in Cell & Developmental Biology
journa l homepage: www.e lsev ier .com/ locate /semcdb
eview
ethylglyoxal metabolism in trypanosomes and leishmania
usan Wyllie, Alan H. Fairlamb∗
ivision of Biological Chemistry and Drug Discovery, Wellcome Trust Biocentre, College of Life Sciences, University of Dundee, Dow Street, Dundee, Angus DD1 5EH, Scotland, UK
r t i c l e i n f o
rticle history:
vailable online 15 February 2011
eywords:
rypanosoma
eishmania
ethylglyoxal
a b s t r a c t
Methylglyoxal is a toxic by-product of glycolysis and other metabolic pathways. In mammalian cells, the
principal route for detoxiﬁcation of this reactive metabolite is via the glutathione-dependent glyoxalase
pathway forming d-lactate, involving lactoylglutathione lyase (GLO1; EC 4.4.1.5) and hydroxyacyl-
glutathione hydrolase (GLO2; EC 3.2.1.6). In contrast, the equivalent enzymes in the trypanosomatid
parasites Trypanosoma cruzi and Leishmania spp. show >200-fold selectivity for glutathionylspermidine
and trypanothione over glutathione and are therefore sensu stricto lactoylglutathionylspermidine lyaseslyoxalase
rypanothione
rug discovery
(EC 4.4.1.-) and hydroxyacylglutathionylspermidine hydrolases (EC 3.2.1.-). The unique substrate speci-
ﬁcityof theparasite glyoxalaseenzymescanbedirectly attributed to theirunusual active site architecture.
The African trypanosome differs from these parasites in that it lacks GLO1 and converts methylglyoxal to
l-lactate rather than d-lactate. Since Trypanosoma brucei is the most sensitive of the trypanosomatids to
methylglyoxal toxicity, the absence of a complete and functional glyoxalase pathway in these parasites
is perplexing. Alternative routes of methylglyoxal detoxiﬁcation in T. brucei are discussed along with the
potential of exploiting trypanosomatid glyoxalase enzymes as targets for anti-parasitic chemotherapy.
© 2011 Elsevier Ltd. 
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. Introduction
Flagellated protozoa of the family Trypanosomatidae encom-
ass a diverse range of organisms, including the human pathogens
rypanosoma brucei, Trypanosoma cruzi and Leishmania spp.,
tively, the diseases are responsible for more than 120,000 fatalities
annually and the loss of over 4,600,000 disability adjusted life
years (DALYs) [1]. Some of the most socio-economically deprived
regions of the world are afﬂicted by these vector-borne para-
Open access under CC BY license.ausative agents of sleeping sickness, Chagas’ disease and leishma-
iasis, respectively. These digenetic parasites undertake complex
ife cycles, differentiating into a variety of developmental forms
hile parasitizing both vertebrate and insect vector hosts. Collec-
Abbreviations: GLO1, glyoxalase I; GLO2, glyoxalase II; T[SH]2, trypanothione,
1,N8-bis(glutathionyl)spermidine;GSH, glutathione; LADH, lactaldehydedehydro-
enase.
∗ Corresponding author. Tel.: +44 1382 385155; fax: +44 1382 385542.
E-mail address: a.h.fairlamb@dundee.ac.uk (A.H. Fairlamb).
084-9521© 2011 Elsevier Ltd. 
oi:10.1016/j.semcdb.2011.02.001
Open access under CC BY license.sites and the accompanying economic burden provides a major
obstacle to improving human health [2]. Almost all existing drugs
used to treat these diseases suffer from serious problems ranging
from severe toxic side effects [3] to acquired drug resistance [4,5].
To further compound these difﬁculties, treatments often require
lengthy periods of hospitalisation and are prohibitively expen-
sive [1]. Therefore, novel drug targets and more effective drug
treatments are urgently required for these neglected diseases of
poverty.
Metabolic pathways that are absent from, or signiﬁcantly dif-
ferent to, host pathways are logical starting points for drug
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Fig. 1. Glycolytic pathway andmetabolic compartments in bloodstream form T. brucei. The shaded inset shows the route tomethylglyoxal from dihydroxyacetone phosphate
(DHAP) and glyceraldehyde 3-phosphate (GA-3P) via an enediol intermediate. Each mol of NADH generated in step 7 is reoxidised via the glycerophosphate shuttle (steps
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ther abbreviations: UQ9 and UQ9H2 are ubiquinone and ubiquinol, respectively.
iscovery. With this in mind, the glyoxalase pathway, a ubiq-
itous detoxiﬁcation pathway that protects against the cellular
amage caused by the toxic and mutagenic glycolytic metabo-
ite methylglyoxal [6,7], would seem far from an ideal drug target
ithin these parasites. The glyoxalase pathway comprises glyox-
lase I (GLO1) (lactoylglutathione lyase, EC 4.4.1.5) and glyoxalase
I (GLO2) (hydroxyacylglutathione hydrolase, EC 3.1.2.6), which
ct in concert to convert the spontaneously formed hemithioac-
tal adduct between glutathione and methylglyoxal into d-lactate
nd glutathione. The universal nature of the glyoxalase pathway
mphasises its signiﬁcance in general cellular function resulting
n its conservation throughout evolution. However, quantitative
ifferences in methylglyoxal metabolism of rapidly proliferating
ells may be therapeutically exploitable. Elevated levels of GLOI,
esponsible for the initial step in the detoxiﬁcation of methylgly-
xal, have been found in tumour tissue from human colon, renal
nd prostate cancers [8] and are believed to be associated with
he increased proliferative growth rates of tumours cells. Most sig-
iﬁcantly, inhibitors of GLO1 have been shown to be selectively
oxic, not only to tumour cells [9], but also to other rapidly growing
rganisms such as the protozoan parasite Plasmodium falciparum
10]. These ﬁndings have raised the possibility that the glyoxalase
athwaymay indeed present a viable drug target in the Trypanoso-
atidae.e 3-phosphate dehydrogenase; 8, phosphoglycerate kinase; 9, phosphoglycerate
dehydrogenase (FAD); 14; ubiquinol oxidase (trypanosome alternative oxidase).
The major source of methylglyoxal in cells is a by-product of
glycolysis, where the triose phosphate intermediates dihydrox-
yacetone phosphate and glyceraldehyde 3-phosphate eliminate
phosphate via an enediolate intermediate (Fig. 1, inset) [6]. Minor
sources of methylglyoxal are from aminoacetone and hydroxy-
acetone, intermediates generated during catabolism of threonine
and acetone [6]. Since T. cruzi, T. brucei and the Leishmania spp.
are known to rapidly proliferate, demands for energy within
cells are particularly high, resulting in high rates of glycolysis.
Indeed, bloodstream-form T. brucei maintain respiratory rates
approximately two orders of magnitude higher than those seen
in mammalian cells [11]. Lacking cytochromes and a functional
tricarboxylic acid cycle, this organism is entirely dependent on
substrate-level phosphorylation from glycolysis for ATP produc-
tion. The major end-product of the glycolytic pathway is pyruvate,
rather than l-lactate, with net production of 2mol of ATP per mol
glucose consumed (Fig. 1). Lacking a canonical l-lactate dehydroge-
nase, NADH is oxidised by means of a plant-like glycerophosphate
oxidase system that is not coupled to oxidative phosphorylation
[12]. Glycolysis is unique in that the initial stages take place within
a microbody-like organelle, the glycosome [13] and reducing
equivalents from NADH are transferred to the mitochondrial glyc-
erophosphate oxidase via the glycerophosphate/dihydroxyacetone
phosphate shuttle. The insect stages of T. brucei and all stages of
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blue) and carboxylate oxygen (red) probes. A rectangle highlights the-glutamate-b
s S-(N-hydroxy-N-p-iodophenylcarbamoyl)glutathione (from PDB 1QIN), a potent i
f the L. major enzyme (PDB2C1) alongside two possible binding conformations of t
. cruzi and Leishmania spp. also possess glycosomes, but are less
ependent on glycolysis for ATP production (∼6–11-fold less than
loodstream forms [14]), because they have a full complement of
ytochromes, partial tricarboxylic acid cycles and are able to use
mino acids or lipids as alternative energy sources.
In the following review, studies which unravelled the unusual
ethylglyoxal metabolism of the trypanosomatids will be dis-
ussed, highlighting the remarkable difference between T. brucei
hat lacks a functional glyoxalase system and T. cruzi and Leish-
ania spp. that do. The potential chemotherapeutic value of this
athway will also be addressed.
. Methylglyoxal detoxiﬁcation in the trypanosomatids
.1. Earliest observations
Until recently, relatively little was known about the glyox-
lase pathway of the trypanosomatids. Early studies of glucose
atabolism in Leishmania braziliensis revealed that these para-
ites released signiﬁcant quantities of d-lactate [15]. Production
f d-lactate in these cells was noted to increase markedly fol-
owing incubation with glucose under anaerobic conditions. Since
-lactate is the end-product of methylglyoxal metabolism via the
lyoxalase pathway, Darling and Blum went on to investigate
he speciﬁc role of methylglyoxal in the production of d-lactate
nd found that L. braziliensis promastigotes, when incubated with
ethylglyoxal, secreted signiﬁcant quantities of d-lactate [16].
hese researchers were also able to detect GSH-dependent GLO1
nd GLO2 activities in sonicated, undialysed lysates of these cells,
onﬁrming the presence of an active glyoxalase pathway appar-
ntly similar to other organisms [16]. Comparative studies ofd- and
-lactate production in a further 4 strains of Leishmania and T. lewisi
onﬁrmed the production of d-lactate by parasites in the pres-
nce of glucose,most signiﬁcantly under anaerobic conditions [17].
ntriguingly, in the same study with T. brucei gambiense, parasites
ailed toproduced-lactatewhen incubatedwithmethylglyoxal, but
xcreted signiﬁcant quantities of l-lactate instead. Since the canon-
cal l-lactate dehydrogenase is absent from African trypanosomes,
his provided the ﬁrst indication that methylglyoxal detoxiﬁcation
echanisms may not be identical across the Trypanosomatidae.
In subsequent studies by Ghoshal and colleagues, Leishmania
onovani promastigotes were also shown to quantitatively convert
ethylglyoxal to d-lactate. However, in this instance, very limited
LO1 and GLO2 activities could be detected in dialysed extracts
f these parasites using GSH as a co-factor [18]. The contrastinge predicted and favourable interaction sites (XSITE) for binding of charged nitrogen
g region; an ellipse, the glycyl carboxylate/amide-binding region. The cyanmolecule
or of the human enzyme. This molecule is also shown modelled into the active site
rmidine group of trypanothione and glutathionylspermidine, shown in green [31].
glyoxalase enzyme activities in dialysed versus undialysed lysates
of L. donovani and L. braziliensis suggested that a factor essential
to glyoxalase activity may have been lost during dialysis. These
observations prompted our laboratory to investigate a role for
the trypanosomatid thiol trypanothione in methylglyoxal detoxi-
ﬁcation. Trypanosomatid parasites are uniquely dependent upon
trypanothione [T[SH]2, N1,N8-bis(glutathionyl) spermidine] [19]
as their principal low molecular-mass thiol, which, together with
trypanothione reductase, assumes many of the anti-oxidant func-
tions commonly undertaken by glutathione [GSH] and glutathione
reductase in their human hosts [20]. This dithiol is primarily
responsible for themaintenance of thiol-redox homeostasis within
trypanosomatids and is crucially involved in the protection of
parasites from oxidative stress [21–23] and heavy metal toxic-
ity [24,25]. The pivotal role T[SH]2 plays in several key metabolic
pathways within these parasites prompted researchers to pose the
question—could T[SH]2 play an equally important role in the detox-
iﬁcation of methylglyoxal in Trypanosoma and Leishmania spp.?
Fifteen years following the initial studies of Darling and Blum,
this lateral shift in thinking re-ignited research of methylglyoxal
metabolism in the trypanosomatids [26,27].
2.2. Glyoxalase I
The metalloenzyme GLO1 isomerises glutathione hemithioac-
etal to S-d-lactoylglutathione, through proton transfer to a
metal-bound enediol intermediate [28]. All previously charac-
terized GLO1 enzymes, both prokaryotic and eukaryotic, utilise
glutathione as a catalytic co-factor. Initial studies to determine
whether T[SH]2 assumes this role in the trypanosomatidswere car-
ried out on the Leishmania major enzyme [26]. While recombinant
GLO1 showed very little activity with glutathione hemithioacetal
substrates, the parasite enzyme was found to be 200-fold more
active with hemithioacetals formed with T[SH]2 and its metabolic
precursor, N1-glutathionylspermidine. Moreover, this enzyme was
also insensitive to glutathione derivatives that are potent inhibitors
of all other characterized GLO1 enzymes. The unique substrate
speciﬁcity demonstrated by L. major GLO1 in this study unequiv-
ocally deﬁnes this enzyme as T[SH]2-dependent and provided the
ﬁrst real evidence that the trypanosomatid glyoxalase pathway is
unique among the eukaryotes.
Unusual substrate speciﬁcity is not the only point of distinc-
tion between L. major GLO1 and other eukaryotic GLO1 enzymes.
Characterisation of the recombinant L. major enzyme revealed a
dependence upon nickel as a metal co-factor [26], in contrast to all
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Table 1
Kinetic parameters of human and trypanosomatid GLO1 enzymes.
GLO1 Methylglyoxal
hemithioacetal substrate
Km, M kcat, s−1 kcat/Km, ×107 M−1 s−1 Relative, kcat/Km
L. major [31]
T[SH]2 32±3 800±30 1.5 60
GspdSH 71±5 1070±40 2.5 100
GSH >1900 ND 0.009 0.36
T. cruzi [32]
T[SH]2 109±10 363±33 3.3 16.5
GspdSH 8.0±0.4 161±12 20 100
GSH >1800 ND 0.0014 0.007
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KHuman [31]
T[SH]2 130±
GspdSH 148±
GSH 49±3
ther eukaryotic glyoxalase enzymes which utilise zinc [29]. This
o-factor speciﬁcity squarely aligns L. major GLO1 with enzymes
rom bacteria such as Escherichia coli, Pseudomonas aeruginosa and
ersinia pestis [30]. Indeed, sequence analysis reveals that L. major
LO1 is most similar to bacterial glyoxalases, sharing 51% iden-
ity at the amino acid level to the equivalent enzyme from the
yanobacteria Synechococcus spp., while sharing only 33% identity
ith human GLO1 [26]. The differences in co-factor and substrate
peciﬁcity in L.majorGLO1 can be directly attributed to the unusual
ctive site architecture, evident in the crystal structure of this
nzyme [31]. In comparison to the human enzyme, L. major GLO1
aintains an increased negative charge and hydrophobic character
ithin its active site which is believed to aid the accommoda-
ion of the positive/aliphatic glycyl-spermidine moiety of T[SH]2
r glutathionylspermidine (Fig. 2). In addition, a loop thought to be
mportant in catalysis in humanGLO1 is truncatedwithin the para-
ite enzyme.Detailed three-dimensional analysis ofhumanGLO1 in
omplex with a transition state analogue, identiﬁed three residues
rucial in ligand binding [29]. Of these residues, Val149 and Lys150
n the human enzyme are replaced by acidic residues Asp100 and
yr101 in both the L. major GLO1 and homologues subsequently
dentiﬁed in both T. cruzi [32] and L. donovani [33]. The conservation
f this uncharged, aromatic and polar residue in the trypanoso-
atidGLO1enzymes at this position suggests that this regionof the
ctive site may well be signiﬁcant in determining substrate speci-
city for hemithioacetal derivatives with glutathionylspermidine
r T[SH]2. Collectively, these structural studies conﬁrm that there
s considerable scope to target trypanosomatidGLO1 enzymeswith
peciﬁc inhibitors. The chemotherapeutic value of such inhibitors
ill be discussed in detail later in this review.
In subsequent years, GLO1 homologues from L. donovani and T.
ruzi have been identiﬁed and characterized [32–34]. Metal recon-
titution experiments showed that T. cruziGLO1was less fastidious
han L. major GLO1 in its divalent metal ion requirement, with
obalt being as equally efﬁcacious as nickel in restoring full enzyme
ctivity [32]. As expected, GLO1 enzymes from these parasites
loselymimicked the L. major enzyme in preferentially isomerising
rypanothionehemithioacetals over those formedwith glutathione
Table 1). Intriguingly, the T. cruzi enzyme showed a higher afﬁnity
or hemithioacetal adducts of glutathionylspermidine, as demon-
able 2
inetic parameters of mammalian and trypanosomatid GLO2 enzymes.
GLO2 Lactoyl-thiol substrate Km
L. donovani [37] T[SH]2 39
GSH ND
T. brucei [27] T[SH]2 16
GSH >30
Mammalian [53] T[SH]2 ND
GSH 19
a Values calculated from published data.104±6 0.08 2.9
83±4 0.06 2.1
1360±40 2.8 100
strated by a markedly lower Km value and a resulting 6-fold higher
speciﬁcity constant, kcat/Km [32]. In light of this observation, glu-
tathionylspermidine adducts would appear to be the most efﬁcient
substrates for TcGLO1. However, it should be noted that trypan-
othione levels are 8-fold higher than glutathionylspermidine in
T. cruzi epimastigotes [21]. Thus, it would seem that both glu-
tathionylspermidine and T[SH]2 hemithioacetal adducts may act
as the physiological substrates of the T. cruzi enzyme in vivo.
Our understanding of metabolic pathways in trypanosomatids
has been greatly facilitated by the sequencing of representative
genomes from the threemajor species: T. brucei, T. cruzi and L.major
[35]. For the ﬁrst time, this endeavour enabled a direct and global
comparison of the metabolic pathways of all three pathogenic par-
asites [36]. One of the most intriguing discoveries arising from
analysis of these genomes was the apparent absence of a gene
encoding a GLO1 homologue in T. brucei. This has since been con-
ﬁrmed experimentally by the absence of detectable GLO1 activity
in T. brucei whole cell extracts and the lack of d-lactate generation
fromwholecells incubatedwithmethylglyoxal [34].Despitehaving
the highest glycolytic rate of all the trypanosomatids, bloodstream
form T. brucei proved to be the least adept of the ‘Tritryp’ para-
sites inmetabolisingmethylglyoxal, ultimately producing l-lactate
rather than d-lactate as a metabolic end-product. The possibility
that these parasites may use an alternative metabolic pathway will
be discussed in detail in a subsequent section.
2.3. Glyoxalase II
The ﬁnal step of methylglyoxal detoxiﬁcation via the gly-
oxalase pathway is catalyzed by GLO2 which converts S-d-
lactoylglutathione into d-lactate and free glutathione. At virtually
the same time that GLO1 was deﬁned as a T[SH]2-dependent
enzyme in L. major, GLO2 from T. brucei was also shown to strongly
prefer thioesters of T[SH]2 as substrates compared to those formed
with glutathione (Table 2) [27]. Indeed, this study was closely fol-
lowed by the identiﬁcation of T[SH]2-dependent GLO2 enzymes in
both L. donovani [37] and T. cruzi [34]. The characterization of GLO2
enzymes which depend upon T[SH]2 as a co-factor in both Leish-
mania spp. and T. cruzi conﬁrms that these parasites maintain a
complete, functional glyoxalase pathway that is signiﬁcantly dif-
, M kcat, s−1a kcat/Km, ×105 M−1 s−1
ND ND
ND ND
4±18 49.2 3.0
00 >4.5 0.015
ND ND
0±1 4.37 0.23
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erent to that of their vertebrate hosts. As in trypanosomatid GLO1
nzymes, the substrate speciﬁcity of GLO2 in these parasites can
e directly related to speciﬁc amino acid substitutions within their
ctive sites. Three basic residues that are known to play a crucial
ole in the binding of the glutathione moiety of GLO2 substrates in
he human enzyme [38] are not conserved in the equivalent par-
site enzymes [39]. It is assumed that these basic residues have
een substituted in order to accommodate the positively charged
hioesters of T[SH]2 or glutathionylspermidine. In addition, the
rystal structure of the GLO2 from L. infantum has revealed the
igniﬁcance of strategically positioned polar residues within the
ctive site responsible for binding the spermidine moiety of the
hioester [39]. The mutually exclusive substrate speciﬁcities and
igniﬁcant differences in active site architecture between human
nd trypanosomatid GLO2 enzymes once again raise hopes that
argeting of the parasite enzyme with speciﬁc inhibitors is an emi-
ently achievable goal.
The retention of GLO2 in the absence of a functional GLO1
nzyme in T. brucei is somewhat perplexing but not entirely with-
ut precedence. Cestode and digenean parasitic helminthes have
een studied that lack GLO1 while maintaining high levels of GLO2
ctivity [40]. Restoration of a functional glyoxalase system in T.
rucei by expression of T. cruzi GLO1 resulted in increased resis-
ance to methylglyoxal and increased conversion of methylglyoxal
o d-lactate, demonstrating that GLO2 is functional in vivo [34].
owever, it has been suggested that the true physiological function
f GLO2 in the African trypanosome is unrelated to the detoxiﬁ-
ation of methylglyoxal [41]. Indeed, recombinant T. brucei GLO2
as demonstrated substrate promiscuity in hydrolyzing S-acetyl-
nd S-proprionyltrypanothione esters with the same catalytic efﬁ-
iency as S-lactoyltrypanothione. The easewithwhich this enzyme
ydrolyses a diverse range of thioesters has led to the hypothesis
hatGLO2may functionas ageneral T[SH]2-thioesterase inT. brucei.
.4. Alternative metabolic pathways for the detoxiﬁcation of
ethylglyoxal
Since methylglyoxal is generated primarily as a by-product of
lycolysis, and the African trypanosome is solely dependent upon
lycolysis for energy, it would be reasonable to assume that T. bru-
ei would preserve robust methylglyoxal-metabolizing systems.
ndeedseveral studieshave showntheseparasites tobeparticularly
ulnerable to methylglyoxal toxicity [34,41], to dihydroxyacetone
oxicity [42] and to a deﬁciency in triose phosphate isomerase
ctivity [43]. In addition, it is noteworthy that the high glycolytic
ux in bloodstream form T. brucei (9900nmolh−1 [108 cells]−1)
44] is associated with the production of l-lactate (30nmol pyru-
ate produced at 37 ◦Ch−1 [108 cells]−1) [34]. Assuming this is
enerated exclusively from the glycolytic pathway this would rep-
esent 0.3% of the carbon ﬂux. Although somewhat higher than
hat of mammalian erythrocytes (0.089%), this correlates with the
igher steady state concentrations of dihydroxyacetone phosphate
nd glyceraldehyde 3-phosphate in bloodstream forms (117 and
M versus 1000 and 69M, respectively for erythrocytes [45]
nd trypanosomes [46]) (recalculated assuming 1g wet weight is
.7×1010 cells and 1×108 cells = 5.8l). These observations pose
he question—in the absence of a functional glyoxalase systemhow
o these parasites protect themselves from this toxic metabolite?
In a previous study, Ghoshal and co-workers identiﬁed
ADPH-dependent methylglyoxal reductase activity in L. donovani
romastigotes [18]. These parasites were shown to metabo-
ize approximately 1% of the exogenous methylglyoxal added to
ultures via this reductase, generating l-lactaldehyde as an end-
roduct. In view of the generation of high levels of l-lactate
y methylglyoxal-treated T. brucei, our laboratory proposed that
ethylglyoxal reductase activity may be elevated in T. bruceivelopmental Biology 22 (2011) 271–277 275
to compensate for the absence of GLO1. Indeed, when NADPH-
dependent methylglyoxal reductase activity was measured in
all three trypanosomatid cell lysates, a two-fold higher reduc-
tase activity was observed in T. brucei procyclic and bloodstream
extracts, compared to that seen in L. major and T. cruzi cells. Bearing
in mind the rates of methylglyoxal metabolism measured in these
cells, elevated methylglyoxal reductase activity could conceivably
account for all methylglyoxal metabolism measured in T. brucei. To
date, a deﬁnitivemethylglyoxal reductase gene has yet to be identi-
ﬁed in T. brucei. However, two putative aldo-keto-reductase genes
(Tb927.2.5180 and Tb11.02.3040) which are members of the same
aldo-keto reductase superfamily as methylglyoxal reductase, have
been annotated in the genome although not functionally charac-
terized. Recent studies have identiﬁed a close homologue of these
enzymes in L. donovani [47]. While this recombinant aldose reduc-
tase was found to effectively reduced methylglyoxal substrates, it
somewhat surprisingly showed a 4-fold preference for glutathione
as a co-factor rather than T[SH]2. Clearly, further studies will be
required to deﬁne both the functionality and thiol-preference of
the putative aldo-keto-reductases from T. brucei.
It is important to note that this hypothesis is not universally
accepted. In a study carried by Krauth-Siegel and co-workers [41],
methylglyoxal reductase activities in bloodstream T. brucei extracts
were found to be 50-fold lower than those detected in our own
study and between 20 and 40 times lower than those measured
in different Leishmania spp. There are no obvious reasons for the
disparate methylglyoxal reductase activities measured in the two
studies, however, it is clear that reductase activities at the lower
level would be unable sustain methylglyoxal metabolism in T. bru-
cei.
To complete the metabolism of methylglyoxal reductase-
generated l-lactaldehyde to l-lactate, T. brucei would require
a functional l-lactaldehyde dehydrogenase. While lactaldehyde
dehydrogenase activity was detected in procyclic T. brucei cell
lysates, a similar activity could not be detected in lysates of
the bloodstream stage of the parasite [34]. Failure to detect
NAD+-dependent lactaldehyde dehydrogenase activities has been
attributed to a high endogenous rate of NADH oxidation in blood-
stream lysatesmasking the formationofNADH.Nevertheless, these
studies conﬁrm that procyclic T. brucei are capable of metabolizing
methylglyoxal to l-lactate. It remains to be seenwhether this is also
true of the bloodstream trypanosome.
In addition to the glyoxalase system and methylglyoxal reduc-
tase, two alternative routes of methylglyoxal detoxiﬁcation have
been described in mammalian cells. These mechanisms of detoxiﬁ-
cation are dependent on methylglyoxal dehydrogenase enzymes,
2-oxaldehyde dehydrogenase and betaine aldehyde dehydroge-
nase [48]. Both enzymes catalyze the oxidation of methylglyoxal
to pyruvate. However, no homologues of these enzymes have been
identiﬁed in the T. brucei genome and neither NAD+ nor NADP+-
dependent methylglyoxal dehydrogenase activities were detected
in T. brucei cell extracts. Thus, the exact mechanisms of methylgly-
oxal detoxiﬁcation in the African trypanosome remain an enigma.
3. Prospects for parasite chemotherapy
The unique substrate speciﬁcities and unusual active site
architecture of trypanosomatid glyoxalase enzymes suggests that
they may be exploitable as targets for anti-parasitic chemother-
apy (Fig. 3). Without question these enzymes can be selectively
targeted by inhibitors based upon their substrate speciﬁcity,
as demonstrated by the potent and speciﬁc inhibition of L.
major GLO1 with S-4-bromobenzyl glutathionylspermidine and
S-4-dinitrophenylglutathionylspermidine [31,34]. Indeed, the gen-
eration of high resolution crystal structures of both the L. major
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T. brucei does not possess a functional GLO system and may metabolize methylglyoxal via methylglyoxal reductase (MeGR) and lactaldehyde dehydrogenase (LADH) to
l s: abs
g genase
G
d
i
g
s
o
a
a
G
t
t
l
i
s
u
u
i
T
g
h
g
g
o
o
a
T
p
m
a
c
i
w-lactate. Solid lines: conﬁrmed metabolic steps in the trypanosomatids; dashed line
reen and blue, respectively. Other abbreviations: MeGDH, methylglyoxal dehydro
LO1 [31] and L. infantum GLO2 [39] has raised hopes that the
esign of more potent and speciﬁc inhibitors of these enzymes
s eminently achievable. However, quantitative assessment of the
lyoxalase pathway of L. infantum by modeling and computer
imulation has recently brought into question the whole validity
f this metabolic pathway as a therapeutic target in these par-
sites [49]. Using experimentally determined kinetic parameters
nd metabolite concentrations, the importance of both GLO1 and
LO2 in maintaining a low intracellular methylglyoxal concentra-
ion within these cells was estimated to be relatively low. In fact,
he rate of methylglyoxal production in cells along with intracellu-
ar T[SH]2 concentrationswere identiﬁed as the critical parameters
n controlling levels of methylglyoxal. With the rationale that the
uccess of this metabolic pathway as a viable drug target relies
pon increasing methylglyoxal concentrations in cells, this sim-
lated study appears to nullify the chemotherapeutic potential of
nhibitors targeted against both glyoxalase enzymes in L. infantum.
hese ﬁndings are in direct contradiction to recent studies of GLO1
ene deletion mutants of L. donovani [50]. Here, Chauhan and Mad-
ubala demonstrated that removal of a single copy of the GLO1
ene by targeted gene replacement resulted in a markedly slower
rowth rate in promastigotes. They went on to show that deletion
f the second genomic copy could only be achieved in the presence
f an episomal “rescue” copy of GLO1, a behaviour that is gener-
lly accepted as indicative of essentiality in Leishmania spp. [51,52].
aken together, these observations support the assertion that GLO1
lays a signiﬁcant and essential role in survival of L. donovani pro-
astigotes andsuggest thatpotent inhibitors targeting this enzymere likely to prove lethal to this pathogenic organism.
In comparison to GLO1, GLO2 may be a less promising target for
hemotherapy. Since the reaction catalyzed by GLO1 is essentially
rreversible under physiological conditions, the inhibition of GLO2
ouldmerely lead to the accumulation of the non-toxicmetaboliteent or unconﬁrmed metabolic steps. T. cruzi, L. major and T. brucei shown in yellow,
; LDH, lactate dehydrogenase.
S-d-lactoyltrypanothione, which, in turn, would be predicted to be
able to displace competitive inhibitors from GLO2. However, this
would be associated with a depletion of glutathionylspermidine
and T[SH]2 cellular content that could disrupt the other essen-
tial metabolic functions of these unique metabolites. To date, the
only genetic studies of GLO2 essentiality in the trypanosomatids
have been in the African trypanosome where RNAi and gene dele-
tion studies in the procyclic form of the parasite demonstrated the
enzyme to be non-essential [41,41]. Since GLO2 is not believed to
play a signiﬁcant role in methylglyoxal detoxiﬁcation in T. brucei,
these ﬁndings have little or no bearing on the essentiality of GLO2
enzymes in the other trypanosomatids. Further genetic and bio-
chemical studies are required to establish the therapeutic value of
inhibitors which target parasitic GLO2 enzymes.
4. Concluding remarks
Our understanding of the glyoxalase pathway in trypanoso-
matid parasites has greatly improved in the last 5–10 years.
Comprehensivebiochemical andmolecular studiesof this pathway,
facilitated by the sequencing of the “TriTryp” genomes, has high-
lightedsigniﬁcantdifferences in theway theseparasitesmetabolize
methylglyoxal. Several studies have suggested that the contrasting
substrate speciﬁcities of thehumanand trypanosomatid glyoxalase
enzymes (GLO1 andGLO2), discussed at length in this review,make
them attractive targets for rational drug design. While this may
well be the case in T. cruzi and Leishmania spp., it is unlikely to
be true in the African trypanosome which lacks a functional gly-
oxalase pathway. Identifying the principal routes of methylglyoxal
detoxiﬁcation in T. brucei is likely to be a focus of future studies
in this ﬁeld. It is hoped that a full understanding of the “unusual”
methylglyoxal metabolism of T. brucei may lead to the discovery of
additional drug targets within these parasites.
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